The UK and US have agreed to a major trade agreement that will guarantee zero import taxes on British medicine products going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that import taxes on these key goods will be held at nothing for a timeframe of the next three years.
This agreement comes after earlier statements to significantly raise tariffs on patented drug products, with potential rates discussed as high as 100%.
"This agreement with the Britain bolsters the global environment for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Commercial Impact
Drugs represent one of the the United Kingdom's largest goods shipped to the US, which is clearly the primary market for leading UK drugmakers.
Trade data indicate that in the year leading up to the third quarter, the UK sold drugs totaling over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that timeframe.
"This agreement secures employment, stimulates capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a government official remarked.
Key British Pledges
The agreement involves several notable commitments from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to increase total public funding on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, refunds exceeded 20%.
Broader Context
The pact follows a protracted tension between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
The disagreement were heightened by arguments that American patients were paying significantly more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a share of its resources over the previous ten-year period.
